Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the genus Cannabis, which includes both hemp and marijuana. It was first identified in 1964 by Gaoni and Mechoulam. CBG is special because it acts as the chemical precursor to other cannabinoids, such as CBD and THC.

Although its availability in the plant is much lower than that of other cannabinoids such as CBD (cannabidiol), in recent years it is attracting the attention of the scientific world because of the benefits it could offer.

It is often referred to as the "mother of all cannabinoids" because other cannabinoids are derived from cannabigerolic acid (CBGA), an acid form of CBG. This means that as the cannabis plant progresses through its life cycle, CBG is converted into THC, CBD and other cannabinoids.

Therapeutic Potential of CBG

While more research is needed to know the exact effects of this cannabinoid and its potential benefits, research shows that CBG could have numerous therapeutic uses.

Although less researched compared to THC and CBD, CBG has been shown to have significant therapeutic potential in preclinical and animal studies. It has been suggested that it may have anti-inflammatory, analgesic, antibacterial and neuroprotective, and even anticancer properties.

It is also thought that this cannabinoid could be an ally to improve people's emotional states, without the problem of side effects that drugs used to treat anxiety and depression usually have.

An important 2020 study published in ACS Infectious Diseases, the infectious diseases journal of the American Chemical Society, whose objective was to evaluate the antimicrobial potential of cannabinoids, [1] showed that CBG is revealed as the most useful cannabinoid against microorganisms that develop resistance to antibiotics, a phenomenon that is increasing every day in today's world.

Similarities and differences between CBG and CBD:

• Both cannabinoids interact with the human body's endocannabinoid system (ECS); a system that regulates a variety of physiological functions, including mood balance, pain, appetite, and immune function.
• Neither produces psychotropic effects and both can be used to counteract the effects of THC, the quintessential psychoactive cannabinoid of the cannabis plant.
• CBG is found in very low concentrations in most cannabis strains, which makes its extraction and large-scale production more difficult and costly compared to CBD, the second most abundant compound in the cannabis plant. However, in recent years, cannabis strains with a higher CBG content have been developed, increasing its availability in products such as oils, tinctures and edibles.
• All indications are that CBG has a better response than CBD in our SEC, which means that its effects can be felt more quickly in the body.

In summary, cannabigerol (CBG) is a non-psychoactive cannabinoid that, with its broad spectrum of properties and benefits, presents itself as a jewel in the world of cannabinoids, although more research is needed to fully understand its effects and benefits in humans, as well as its therapeutic applications. However, everything seems to point to the fact that as more scientific evidence accumulates, it is possible that more potential uses for this cannabinoid in the medical and health field will be identified.

As with any cannabis-related compound, it is important to consult with a healthcare professional before using CBG-containing products, especially if medicinal use is being considered.

[1] "Uncovering the Hidden Antibiotic Potential of Cannabis". Reference from www.fundacion-canna.es/cannabigerol-el-potencial-del-cannabis-en-futuras-crisis-sanitarias